Xeris Biopharma Holdings (XERS) Interest Expenses (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Interest Expenses came in at $8.6 million in Q1 2026, little changed YoY from $8.6 million in Q1 2025, and up 20.04% on a QoQ basis from $7.2 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Interest Expenses (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Interest Expenses data on file, last reported at $8.6 million in Q1 2026.
- Quarterly Interest Expenses changed 0.0% year-over-year to $8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (changed 0.0% YoY) and the FY2025 annual result came in at $43.2 million, down 78.3% from the prior year.
- Interest Expenses improved to $8.6 million in Q1 2026, from $7.2 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $77.8 million in Q2 2022 to a low of $3.2 million in Q4 2022.
- A 5-year average of $13.6 million and a median of $8.6 million in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses jumped 4221.39% — and 2023, when it sank 88.89%.
- Tracing XERS's Interest Expenses over 5 years: stood at $3.2 million in 2022, then jumped by 121.39% to $7.0 million in 2023, then decreased by 14.18% to $6.0 million in 2024, then grew by 19.54% to $7.2 million in 2025, then advanced by 20.04% to $8.6 million in 2026.
- The last three Interest Expenses figures came in at $8.6 million (Q1 2026), $7.2 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | -400.56 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 2.90 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 120.70 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 2.90 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 59.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.37 Bn | 79.59 Mn | 6.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61.52 Mn |
| Jun 30, 2026 | 61.52 Mn |
| Mar 31, 2026 | 8.64 Mn |
| Mar 31, 2026 | 8.64 Mn |
| Dec 31, 2025 | 7.20 Mn |
| Dec 31, 2025 | 7.20 Mn |
| Sep 30, 2025 | 8.64 Mn |
| Sep 30, 2025 | 8.64 Mn |
| Jun 30, 2025 | 29.08 Mn |
| Jun 30, 2025 | 29.08 Mn |
| Mar 31, 2025 | 8.64 Mn |
| Mar 31, 2025 | 8.64 Mn |
| Dec 31, 2024 | 6.02 Mn |
| Dec 31, 2024 | 6.02 Mn |
| Sep 30, 2024 | 8.64 Mn |
| Sep 30, 2024 | 8.64 Mn |
| Jun 30, 2024 | 8.64 Mn |
| Jun 30, 2024 | 8.64 Mn |
| Mar 31, 2024 | 8.64 Mn |
| Mar 31, 2024 | 8.64 Mn |